CHRS
Price
$0.81
Change
+$0.01 (+1.25%)
Updated
Jul 3 closing price
Capitalization
93.91M
24 days until earnings call
FHTX
Price
$5.13
Change
+$0.18 (+3.64%)
Updated
Jul 3 closing price
Capitalization
285.95M
36 days until earnings call
Interact to see
Advertisement

CHRS vs FHTX

Header iconCHRS vs FHTX Comparison
Open Charts CHRS vs FHTXBanner chart's image
Coherus Oncology
Price$0.81
Change+$0.01 (+1.25%)
Volume$679.4K
Capitalization93.91M
Foghorn Therapeutics
Price$5.13
Change+$0.18 (+3.64%)
Volume$80.45K
Capitalization285.95M
CHRS vs FHTX Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FHTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. FHTX commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and FHTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (CHRS: $0.81 vs. FHTX: $5.13)
Brand notoriety: CHRS and FHTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 49% vs. FHTX: 60%
Market capitalization -- CHRS: $93.91M vs. FHTX: $285.95M
CHRS [@Biotechnology] is valued at $93.91M. FHTX’s [@Biotechnology] market capitalization is $285.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileFHTX’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • FHTX’s FA Score: 0 green, 5 red.
According to our system of comparison, FHTX is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 3 TA indicator(s) are bullish while FHTX’s TA Score has 4 bullish TA indicator(s).

  • CHRS’s TA Score: 3 bullish, 3 bearish.
  • FHTX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, FHTX is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а +10.57% price change this week, while FHTX (@Biotechnology) price change was +5.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

FHTX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FHTX($286M) has a higher market cap than CHRS($93.9M). FHTX YTD gains are higher at: 8.686 vs. CHRS (-41.304). CHRS has higher annual earnings (EBITDA): 80.2M vs. FHTX (-91.89M). FHTX has more cash in the bank: 221M vs. CHRS (82.4M). FHTX has less debt than CHRS: FHTX (34.9M) vs CHRS (270M). CHRS has higher revenues than FHTX: CHRS (272M) vs FHTX (23.5M).
CHRSFHTXCHRS / FHTX
Capitalization93.9M286M33%
EBITDA80.2M-91.89M-87%
Gain YTD-41.3048.686-476%
P/E Ratio1.84N/A-
Revenue272M23.5M1,157%
Total Cash82.4M221M37%
Total Debt270M34.9M774%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
12

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSFHTX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bullish Trend 5 days ago
66%
Bullish Trend 5 days ago
89%
MACD
ODDS (%)
Bullish Trend 5 days ago
64%
Bullish Trend 5 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 5 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
70%
Bullish Trend 5 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 5 days ago
86%
Declines
ODDS (%)
Bearish Trend 25 days ago
88%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
84%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FHTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SREMF0.820.02
+2.50%
Sunrise Energy Metals Ltd.
JGSMY6.53N/A
N/A
JG Summit Holdings, Inc.
MRCHF20.69N/A
N/A
Miraca Holdings, Inc.
NEMCL58.00N/A
N/A
Newmont Corporation
FKMCF0.10N/A
-3.45%
FOKUS MNG CORP.

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+1.87%
XENE - CHRS
39%
Loosely correlated
-0.33%
RXRX - CHRS
35%
Loosely correlated
+1.15%
FHTX - CHRS
34%
Loosely correlated
+3.64%
IPSC - CHRS
34%
Loosely correlated
+0.02%
SRRK - CHRS
33%
Loosely correlated
+1.24%
More

FHTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, FHTX has been loosely correlated with ABOS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if FHTX jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FHTX
1D Price
Change %
FHTX100%
+3.64%
ABOS - FHTX
54%
Loosely correlated
+2.65%
IPSC - FHTX
49%
Loosely correlated
+0.02%
IMNM - FHTX
48%
Loosely correlated
+2.43%
CRSP - FHTX
48%
Loosely correlated
+0.97%
NAUT - FHTX
47%
Loosely correlated
+4.73%
More